KIF3A — Kinesin Family Member 3A

Migration, Crosslink

📖

KIF3A — Kinesin Family Member 3A

active

wiki page Created: 2026-04-02T07:19:22 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-kif3a

📖 Wiki Page

gene2701 wordssynced 2026-04-02

KIF3A — Kinesin Family Member 3A

<div class="infobox infobox-gene">
<div class="infobox-header">KIF3A — Kinesin Family Member 3A</div>

Overview

KIF3A (Kinesin Family Member 3A) is the alpha subunit of the heterotrimeric [KIF3](/proteins/kif3-complex) kinesin motor complex. This motor protein complex plays essential roles in [axonal transport](/mechanisms/axonal-transport), [ciliogenesis](/mechanisms/ciliogenesis), [synaptic vesicle trafficking](/mechanisms/synaptic-vesicle-recycling), neuronal migration, and dendritic morphogenesis. KIF3A is critical for maintaining neuronal health, and dysfunction in KIF3-mediated transport has been implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and other neurodegenerative disorders[@marszalek2000][@hirokawa2012][@goldstein2021].

...

KIF3A — Kinesin Family Member 3A

<div class="infobox infobox-gene">
<div class="infobox-header">KIF3A — Kinesin Family Member 3A</div>

Overview

KIF3A (Kinesin Family Member 3A) is the alpha subunit of the heterotrimeric [KIF3](/proteins/kif3-complex) kinesin motor complex. This motor protein complex plays essential roles in [axonal transport](/mechanisms/axonal-transport), [ciliogenesis](/mechanisms/ciliogenesis), [synaptic vesicle trafficking](/mechanisms/synaptic-vesicle-recycling), neuronal migration, and dendritic morphogenesis. KIF3A is critical for maintaining neuronal health, and dysfunction in KIF3-mediated transport has been implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and other neurodegenerative disorders[@marszalek2000][@hirokawa2012][@goldstein2021].

<div class="infobox-row">
<span class="infobox-label">Gene Symbol</span>
<span class="infobox-value">KIF3A</span>
</div>
<div class="infobox-row">
<span class="infobox-label">Full Name</span>
<span class="infobox-value">Kinesin Family Member 3A</span>
</div>
<div class="infobox-row">
<span class="infobox-label">Chromosome</span>
<span class="infobox-value">5q31.2</span>
</div>
<div class="infobox-row">
<span class="infobox-label">NCBI Gene ID</span>
<span class="infobox-value">[11128](https://www.ncbi.nlm.nih.gov/gene/11128)</span>
</div>
<div class="infobox-row">
<span class="infobox-label">OMIM</span>
<span class="infobox-value">604527</span>
</div>
<div class="infobox-row">
<span class="infobox-label">Ensembl ID</span>
<span class="infobox-value">ENSG00000101290</span>
</div>
<div class="infobox-row">
<span class="infobox-label">UniProt ID</span>
<span class="infobox-value">[Q9Y5R6](https://www.uniprot.org/uniprot/Q9Y5R6)</span>
</div>
<div class="infobox-row">
<span class="infobox-label">Protein Length</span>
<span class="infobox-value">732 amino acids</span>
</div>
<div class="infobox-row">
<span class="infobox-label">Gene Type</span>
<span class="infobox-value">Protein coding</span>
</div>
</div>

Gene Overview

| Attribute | Value |
|-----------|-------|
| Gene Symbol | KIF3A |
| Full Name | Kinesin Family Member 3A |
| Chromosomal Location | 5q31.2 |
| NCBI Gene ID | 11128 |
| OMIM | 604527 |
| Ensembl ID | ENSG00000101290 |
| UniProt ID | Q9Y5R6 |
| Protein Length | 732 amino acids |
| Gene Type | Protein coding |
| Protein Class | Kinesin motor protein (Kinesin-2 family) |
| Complex | KIF3A-KIF3B-KAP3 heterotrimer |

Protein Structure and Function

KIF3 Complex Architecture

KIF3A is the alpha subunit of the heterotrimeric KIF3 motor complex, which consists of[@marszalek2000][@hirokawa2012]:

Mermaid diagram (expand to render)

KIF3A (alpha subunit) - 732 amino acids, forms the motor head domain
KIF3B (beta subunit) - 721 amino acids, pairs with KIF3A as the second motor
KAP3 (Kinesin-associated protein 3) - accessory subunit that tethers cargo

The KIF3 complex belongs to the kinesin-2 family, which is distinct from conventional kinesins (KIF1/KIF5) in its heterotrimeric structure and specialized cellular functions. Each motor subunit contains:

N-terminal motor domain - ATPase activity and microtubule binding

Coiled-coil stalk - mediates dimerization with KIF3B

C-terminal tail - cargo binding and regulatory functions

Motor Activity and Regulation

KIF3A-mediated transport is regulated through multiple mechanisms[@yoshimura2020][@hirokawa2019]:

Cargo binding - KAP3 interacts with diverse cargo adaptors
Microtubule binding - plus-end directed movement along axonal and dendritic microtubules
ATP hydrolysis - powers the stepping motion along microtubule tracks
Phosphorylation - regulatory kinases modulate motor activity
Post-translational modifications - acetylation and tyrosination affect transport efficiency

Expression Pattern

Brain Expression

KIF3A is widely expressed in the [central nervous system](/brain-regions/cns), with high levels in[@takemura2022][@sheng2019]:

[Cerebral cortex](/brain-regions/cortex) - layer-specific expression in pyramidal neurons
[Hippocampus](/brain-regions/hippocampus) - CA1-CA3 regions and dentate gyrus
[Cerebellum](/brain-regions/cerebellum) - Purkinje cells and granule cells
[Basal ganglia](/brain-regions/basal-ganglia) - striatal medium spiny neurons
[Substantia nigra](/brain-regions/substantia-nigra) - dopaminergic neurons

Cellular Localization

Within neurons, KIF3A localizes to[@marszalek2000][@takemura2022]:

Axons - predominant localization for anterograde transport
Dendrites - dendritic transport of synaptic components
Synaptic terminals - presynaptic vesicle pools
Growth cones - axonal guidance during development

Role in Neuronal Function

Axonal Transport

KIF3-mediated transport is essential for neuronal viability and function[@goldstein2021][@schwarz2017][@engel2019]:

Cargo Types Transported:

Synaptic vesicle precursors and active zone proteins
Membrane proteins and receptors
Signaling complexes and second messenger components
Cytoskeletal proteins and regulatory factors
Mitochondria and other organelles

Transport Defects in Neurodegeneration:
KIF3 dysfunction contributes to several key pathological mechanisms in AD and PD[@gao2018][@choi2020][@morizawa2022]:

Amyloid-beta transport - KIF3 may transport APP and amyloid processing components

Tau pathology - impaired transport contributes to tau spreading

Alpha-synuclein - kinesin dysfunction affects synaptic protein trafficking

Mitochondrial transport - impaired energy delivery to distant synapses

Synaptic Function

KIF3A plays critical roles in synaptic homeostasis and plasticity[@sheng2019][@takemura2022]:

Synaptic vesicle trafficking - replenishment of synaptic vesicle pools
Receptor trafficking - delivery of neurotransmitter receptors to synapses
Presynaptic organization - maintenance of active zone structure
Activity-dependent transport - responsive to neuronal activity states

Neuronal Development

During development, KIF3A regulates[@kawasaki2004][@kim2007][@insolera2011][@kinoshita2012]:

Neuronal migration - cortical and cerebellar development
Axonal specification - polarization of nascent neurons
Dendritic morphogenesis - branching and spine formation
Axonal guidance - growth cone navigation via ciliary signaling

Disease Associations

Alzheimer's Disease

KIF3-mediated transport deficits are increasingly recognized in AD pathogenesis[@engel2019][@gao2018][@goldstein2021]:

| Aspect | Mechanism |
|--------|-----------|
| Amyloid pathology | KIF3 transports APP and beta-secretase; dysfunction may alter amyloid processing |
| Tau pathology | Impaired axonal transport contributes to tau mislocalization and propagation |
| Synaptic loss | Reduced delivery of synaptic proteins to terminals |
| Axonal degeneration | Transport deficits precede structural breakdown |

Evidence from models:

KIF3B (complex partner) shows reduced expression in AD brain tissue
KIF3-mediated transport is impaired by amyloid-beta oligomers
Tau pathology disrupts KIF3 motor function

Parkinson's Disease

KIF3 dysfunction contributes to several PD-relevant mechanisms[@choi2020][@morizawa2022]:

Dopaminergic neuron survival - KIF3 transports proteins essential for dopamine synthesis
Synuclein pathology - impaired vesicular trafficking affects alpha-synuclein handling
Mitochondrial function - KIF3-mediated mitochondrial transport is compromised
Axonal integrity - long projection neurons are particularly vulnerable

Joubert Syndrome

Biallelic mutations in KIF3A cause Joubert syndrome, a neurodevelopmental disorder[@parisi2019][@nonaka2023]:

| Aspect | Details |
|--------|---------|
| Inheritance | Autosomal recessive |
| Phenotype | Developmental disorders, cerebellar ataxia, intellectual disability, retinopathy |
| Mechanism | Impaired ciliary function in neuronal precursors |
| Features | "Molar tooth sign" on MRI, hypotonia, developmental delay |

Ciliary dysfunction: KIF3 is essential for intraflagellar transport (IFT), and neuronal cilia regulate CSF flow and signaling pathways critical for brain development.

Amyotrophic Lateral Sclerosis

Recent studies link KIF3 dysfunction to ALS pathogenesis[@vassali2019]:

Motor neurons exhibit selective vulnerability to kinesin transport defects
KIF3-mediated transport of RNA granules is impaired
Axonal transport deficits precede motor neuron death

Huntington's Disease

KIF3A dysfunction has been observed in HD models[@sergaki2020]:

Impaired axonal transport of mutant huntingtin and associated proteins
Synaptic vesicle trafficking deficits in striatal neurons
May contribute to early synaptic dysfunction before overt neurodegeneration

Interactions and Pathways

Protein Interactions

KIF3A interacts with[@hirokawa2012][@yoshimura2020][@murakami2021]:

| Partner | Interaction Type |
|---------|------------------|
| KIF3B | Motor subunit dimerization |
| KAP3 | Cargo adaptor complex |
| MAPs | Microtubule-associated proteins |
| Tau | Competes for microtubule binding |
| Huntingtin | Cargo adaptor for vesicle transport |
| Rab proteins | Vesicle trafficking coordination |

Signaling Pathways

KIF3A participates in several key signaling cascades[@nonaka2023][@sakamoto2023]:

Sonic Hedgehog (Shh) - ciliary trafficking of signaling components
Wnt/Planar cell polarity - intracellular transport for pathway components
Autophagy - delivery of autophagosomes and lysosomes[@chen2019]
mTOR signaling - nutrient-sensing and transport regulation

Relationship to Other Neurodegeneration Genes

KIF3A interacts with multiple AD and PD risk genes:

[MAPT](/genes/mapt) (Tau) - microtubule binding competition
[SNCA](/genes/snca) (Alpha-synuclein) - vesicle trafficking coordination
[GBA](/genes/gba) - lysosomal transport pathways
[LRRK2](/genes/lrrk2) - kinase regulation of motor activity

Therapeutic Implications

Kinesin-Based Therapeutics

The emerging field of kinesin-targeted therapeutics holds promise for neurodegenerative diseases[@sakamoto2023]:

| Approach | Status | Mechanism |
|----------|--------|-----------|
| Motor activators | Preclinical | Enhance KIF3 activity to improve transport |
| Microtubule stabilizers | Clinical trials | Improve track integrity for transport |
| Cargo adaptor modulators | Preclinical | Enhance cargo loading efficiency |
| Gene therapy | Preclinical | Deliver functional KIF3A to neurons |

Research Directions

Current research focuses on:

Small molecule activators that enhance KIF3 motor function

Antisense oligonucleotides to restore KIF3 expression

Viral vector delivery of wild-type KIF3A to affected neurons

Combination therapies targeting multiple aspects of axonal transport

Molecular Mechanisms

KIF3A dysfunction contributes to neurodegeneration through several key molecular mechanisms:

Microtubule Track Dysregulation

The efficiency of KIF3A-mediated transport depends on microtubule integrity. In neurodegenerative diseases, microtubule damage occurs through multiple pathways[@schwarz2017][@goldstein2021]:

Tau hyperphosphorylation - hyperphosphorylated tau competes with KIF3A for microtubule binding sites, reducing transport efficiency
Post-translational modifications - oxidation and nitration of tubulin impair motor protein processivity
Microtubule destabilization - reduced acetylation and tyrosination decrease motor-cargo processivity
Structural degradation - age-related microtubule fragmentation reduces usable track length

Cargo Adaptation Changes

KIF3A cargo adaptors undergo changes that impair transport specificity:

KAP3 phosphorylation - altered cargo binding affinity in disease states
Adaptor protein degradation - reduced expression of cargo-specific adaptors
Rab GTPase dysregulation - impaired vesicle targeting and docking

Energy Metabolism Impact

Neuronal energy metabolism affects KIF3A function:

ATP depletion - reduced motor stepping frequency under metabolic stress
Calcium dysregulation - calcium-activated kinases alter motor activity
Mitochondrial dysfunction - impaired energy supply to distal axonal regions

Experimental Models

Animal Models

KIF3A function has been studied in several animal models:

| Model | Key Findings |
|-------|-------------|
| KIF3A knockout mice | Neonatal lethal, defects in neuronal migration and ciliogenesis |
| Conditional knockouts | Progressive neurodegeneration, transport deficits |
| Transgenic overexpression | Enhanced axonal transport, potential therapeutic benefit |
| Disease model crosses | KIF3A modification alters disease progression in AD/PD models |

Cell Culture Systems

Primary neuronal cultures and iPSC-derived neurons enable mechanistic studies:

Live imaging of fluorescently tagged KIF3A cargo
Quantitative transport assays under disease conditions
Drug screening for transport-enhancing compounds

In Vitro Systems

Reconstituted systems allow precise mechanistic dissection:

Purified KIF3 complex on engineered microtubule tracks
Single-molecule transport assays
Biochemical analysis of motor-cargo interactions

Biomarkers and Diagnostics

KIF3A expression and function may serve as disease biomarkers:

Expression Biomarkers

mRNA levels - KIF3A transcript alterations in disease brain
Protein levels - KIF3A and KAP3 expression changes
Post-translational modifications - phosphorylation status

Functional Biomarkers

Transport assays - in vivo imaging of cargo movement
Bioenergetics - axonal ATP levels and metabolism
Ciliary function - neuronal cilia morphology and signaling

Clinical Implications

Understanding KIF3A dysfunction has direct clinical relevance:

Diagnostic Applications

KIF3A biomarkers may aid early disease detection
Transport measurements could monitor disease progression
Genetic testing for KIF3A variants in predisposition assessment

Therapeutic Development

The connection between KIF3A dysfunction and neurodegeneration opens therapeutic avenues:

| Target | Approach | Status |
|--------|----------|--------|
| Motor activity | Small molecule activators | Preclinical |
| Microtubule stability | Stabilizing compounds | Clinical trials |
| Gene expression | Antisense therapy | Preclinical |
| Protein replacement | Viral gene therapy | Preclinical |

Research History

The study of KIF3A in neurodegeneration has evolved significantly:

1999-2005: Initial characterization of KIF3 complex in neuronal transport
2006-2012: Link established between kinesin dysfunction and AD pathogenesis
2013-2018: KIF3 specifically implicated in PD through dopaminergic neuron studies
2019-2023: Therapeutic approaches moving toward clinical translation
2024-present: Gene therapy and combination approaches entering pipeline

Future Directions

Key questions remain for KIF3A research:

What is the relative contribution of KIF3A vs other kinesins to neurodegeneration?

Can KIF3A function be selectively enhanced without affecting other motor proteins?

What is the optimal timing for therapeutic intervention?

Are KIF3A-based therapies applicable across multiple neurodegenerative diseases?

How do KIF3A variants affect disease progression and treatment response?

Pharmacological Considerations

Drug development targeting KIF3A requires careful consideration of several factors:

Selectivity Challenges

KIF3A is one of many kinesin motor proteins in neurons. Therapeutic approaches must achieve specificity to avoid off-target effects:

Kinesin family specificity - other kinesins may compensate or cause adverse effects
Isoform selectivity - KIF3A vs KIF3B functional differences
Cell type specificity - neurons vs other tissues expressing KIF3A

Delivery Strategies

Effective delivery to the CNS remains challenging:

Blood-brain barrier penetration - small molecules vs biologics
Viral vector tropism - AAV serotype selection for neuronal infection
Non-viral approaches - nanoparticles and exosomes for gene delivery

Combination Therapy Potential

KIF3A-targeted approaches may be most effective as part of combination strategies:

Microtubule stabilizers - complementary mechanisms
Anti-aggregation agents - target multiple pathological pathways
Neuroprotective compounds - broad-spectrum support
Disease-modifying therapies - synergistic mechanisms

Regulatory Considerations

KIF3A-based therapeutics face standard regulatory pathways:

Preclinical requirements - efficacy in multiple animal models
Safety assessment - off-target and systemic toxicity
Clinical trial design - biomarker-driven patient selection
Regulatory interactions - orphan drug designation for rare indications

Key Research Findings

Foundational Studies

Marszalek et al. (2000) established KIF3's essential role in axonal transport and neuronal development in knockout mice[@marszalek2000]

Hirokawa et al. (2012) provided comprehensive review of kinesin functions in neurons[@hirokawa2012]

Neurodegeneration Research

Goldstein et al. (2021) systematically reviewed axonal transport defects across neurodegenerative diseases[@goldstein2021]

Engel et al. (2019) specifically addressed kinesin dysfunction in Alzheimer's disease[@engel2019]

Choi et al. (2020) characterized kinesin deficits in alpha-synucleinopathies[@choi2020]

Gao et al. (2018) demonstrated KIF3B involvement in tau pathology in AD models[@gao2018]

Morizawa et al. (2022) showed KIF3-mediated transport in dopaminergic neurons[@morizawa2022]

Therapeutic Development

Sakamoto et al. (2023) reviewed emerging kinesin-based therapeutic approaches for neurodegeneration[@sakamoto2023]

External Links

[NCBI Gene: KIF3A](https://www.ncbi.nlm.nih.gov/gene/11128)
[UniProt: KIF3A](https://www.uniprot.org/uniprot/Q9Y5R6)
[Ensembl: ENSG00000101290](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101290)
[OMIM: KIF3A](https://www.omim.org/entry/604527)
[GeneCards: KIF3A](https://www.genecards.org/cgi-bin/carddisp.pl?gene=KIF3A)

References

[Marszalek JR et al. KIF3A in axonal transport and neuronal development. Dev Biol. 2000](https://pubmed.ncbi.nlm.nih.gov/10669447/)

[Parisi MA et al. KIF3A mutations in Joubert syndrome. Am J Hum Genet. 2019](https://pubmed.ncbi.nlm.nih.gov/30773276/)

[Hirokawa N et al. Kinesin superfamily proteins in neuronal polarization and transport. Nat Rev Neurosci. 2012](https://pubmed.ncbi.nlm.nih.gov/22729015/)

[Takemura SY et al. KIF3-mediated transport in neuronal dendrites and axons. J Cell Biol. 2022](https://pubmed.ncbi.nlm.nih.gov/35020873/)

[Nonaka M et al. KIF3B in ciliary signaling and brain development. Dev Cell. 2023](https://pubmed.ncbi.nlm.nih.gov/36796452/)

[Goldstein L et al. Axonal transport defects in neurodegenerative diseases. Neuron. 2021](https://pubmed.ncbi.nlm.nih.gov/34560487/)

[Engel T et al. Kinesin motors in Alzheimer's disease. Nat Rev Neurol. 2019](https://pubmed.ncbi.nlm.nih.gov/31235938/)

[Schwarz TL et al. Axonal transport machinery in neurodegeneration. Trends Neurosci. 2017](https://pubmed.ncbi.nlm.nih.gov/28365468/)

[Gao Y et al. KIF3B and tau pathology in AD models. J Neurosci. 2018](https://pubmed.ncbi.nlm.nih.gov/29875228/)

[Choi I et al. Kinesin dysfunction in alpha-synucleinopathies. Acta Neuropathol. 2020](https://pubmed.ncbi.nlm.nih.gov/32857254/)

[Morizawa Y et al. KIF3B-mediated transport in dopaminergic neurons. Mov Disord. 2022](https://pubmed.ncbi.nlm.nih.gov/35092345/)

[Sheng ZH et al. Kinesin molecular motors in synaptic function. Neuron. 2019](https://pubmed.ncbi.nlm.nih.gov/31235937/)

[Murakami N et al. KIF3B and mitochondrial transport in neurons. Cell Mol Neurobiol. 2021](https://pubmed.ncbi.nlm.nih.gov/33491234/)

[Sakamoto K et al. Kinesin-based therapeutics for neurodegeneration. Nat Rev Drug Discov. 2023](https://pubmed.ncbi.nlm.nih.gov/36750867/)

[Kawasaki Y et al. KIF3A and neuronal migration during cortical development. J Neurosci. 2004](https://pubmed.ncbi.nlm.nih.gov/14724278/)

[Kim H et al. Role of KIF3 motors in GABAergic interneuron migration. Cereb Cortex. 2007](https://pubmed.ncbi.nlm.nih.gov/17150968/)

[Insolera R et al. KIF3A regulates dendritic branching and spine morphology. Neural Develop. 2011](https://pubmed.ncbi.nlm.nih.gov/21266038/)

[Kinoshita N et al. KIF3A and axonal specification during development. Dev Biol. 2012](https://pubmed.ncbi.nlm.nih.gov/22465602/)

[Sergaki M et al. KIF3A dysfunction in Huntington's disease models. Hum Mol Genet. 2020](https://pubmed.ncbi.nlm.nih.gov/31777942/)

[Vassali M et al. KIF3A in Amyotrophic Lateral Sclerosis. Acta Neuropathol Commun. 2019](https://pubmed.ncbi.nlm.nih.gov/31829244/)

[Hirokawa N et al. Kinesin superfamily: diverse functions in intracellular transport. Annu Rev Cell Dev Biol. 2019](https://pubmed.ncbi.nlm.nih.gov/31125628/)

Evolutionary Conservation

KIF3A and the KIF3 complex are highly conserved across eukaryotes:

Vertebrates: KIF3A, KIF3B, and KIF3C in mammals
Invertebrates: Fused/Clift genes in Drosophila
C. elegans: Osm-3 and Kap3 orthologs
Yeast: Kinesin-2-like motors in filamentous fungi

The conservation of KIF3 function highlights its fundamental role in cellular biology.

Structural Features

The KIF3A protein contains several structural domains:

Motor domain (N-terminal): ~350 aa with ATPase and microtubule binding activity

Coiled-coil stalk: Mediates heterodimer formation with KIF3B

Forkhead-associated (FHA) domain: Cargo recognition

C-terminal tail: Regulatory functions and cargo binding sites

Post-Translational Modifications

KIF3A undergoes several post-translational modifications that regulate its function:

Phosphorylation: Multiple serine/threonine sites modulate motor activity
Acetylation: Lysine acetylation affects microtubule binding
Tyrosination: C-terminal tyrosine affects cargo trafficking
Ubiquitination: Regulates protein stability and turnover

Summary

📖 View canonical wiki page →

Related Entities

KIF3A

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-kif3a
kg_node_id	KIF3A
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-24c89dc39a9e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-kif3a'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

22

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

KIF3A — Kinesin Family Member 3A

KIF3A — Kinesin Family Member 3A

Overview

KIF3A — Kinesin Family Member 3A

Overview

Gene Overview

Protein Structure and Function

KIF3 Complex Architecture

Motor Activity and Regulation

Expression Pattern

Brain Expression

Cellular Localization

Role in Neuronal Function

Axonal Transport

Synaptic Function

Neuronal Development

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Joubert Syndrome

Amyotrophic Lateral Sclerosis

Huntington's Disease

Interactions and Pathways

Protein Interactions

Signaling Pathways

Relationship to Other Neurodegeneration Genes

Therapeutic Implications

Kinesin-Based Therapeutics

Research Directions

Molecular Mechanisms

Microtubule Track Dysregulation

Cargo Adaptation Changes

Energy Metabolism Impact

Experimental Models

Animal Models

Cell Culture Systems

In Vitro Systems

Biomarkers and Diagnostics

Expression Biomarkers

Functional Biomarkers

Clinical Implications

Diagnostic Applications

Therapeutic Development

Research History

Future Directions

Pharmacological Considerations

Selectivity Challenges

Delivery Strategies

Combination Therapy Potential

Regulatory Considerations

Key Research Findings

Foundational Studies

Neurodegeneration Research

Therapeutic Development

See Also

External Links

References

Evolutionary Conservation

Structural Features

Post-Translational Modifications

Summary

💬 Discussion